• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.

作者信息

Delafosse Marion, Ponlot Eléonore, Esteve Emmanuel, Ghislain Louise, Hanset Nicolas, Boffa Jean-Jacques, Johanet Catherine, Dahan Karine

机构信息

Sorbonne Université, UMR_S 1155, Paris, France; Institut National de la Santé et de la Recherche Médicale UMR_S 1155, Paris, France; Département Néphrologie et Dialyses, Tenon Hospital, AP-HP, Paris, France.

Département Néphrologie et Dialyses, Tenon Hospital, AP-HP, Paris, France.

出版信息

Kidney Int. 2021 Apr;99(4):1023-1024. doi: 10.1016/j.kint.2020.12.029.

DOI:10.1016/j.kint.2020.12.029
PMID:33745532
Abstract
摘要

相似文献

1
Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.个性化磷脂酶A2受体抗体驱动的利妥昔单抗治疗膜性肾病策略
Kidney Int. 2021 Apr;99(4):1023-1024. doi: 10.1016/j.kint.2020.12.029.
2
Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.磷脂酶A2受体（PLA2R）抗体相关膜性肾病的免疫缓解：环磷酰胺与利妥昔单抗对比
Kidney Int. 2018 Apr;93(4):1016-1017. doi: 10.1016/j.kint.2017.12.019.
3
STARMEN: progress in membranous nephropathy?
Kidney Int. 2021 May;99(5):1242-1243. doi: 10.1016/j.kint.2021.01.025.
4
Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.他克莫司联合皮质类固醇与改良庞蒂切利方案治疗特发性膜性肾病的随机对照试验
Nephrology (Carlton). 2016 Feb;21(2):139-46. doi: 10.1111/nep.12569.
5
Membranous nephropathy: setting the bar for hypothesis-driven, selective therapies in nephrology.膜性肾病：为肾脏病学中基于假设驱动的选择性疗法设定标准。
J Nephrol. 2021 Apr;34(2):561-563. doi: 10.1007/s40620-020-00806-0.
6
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.近期原发性膜性肾病治疗的临床试验观察
Drugs. 2022 Feb;82(2):109-132. doi: 10.1007/s40265-021-01656-1. Epub 2021 Dec 21.
7
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO.利妥昔单抗治疗膜性肾病优于环磷酰胺：支持观点。
Kidney360. 2021 Apr 19;2(11):1696-1698. doi: 10.34067/KID.0001842021. eCollection 2021 Nov 25.
8
Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.儿童特发性膜性肾病用利妥昔单抗治疗：两例报告。
Pediatr Nephrol. 2018 Jun;33(6):1089-1092. doi: 10.1007/s00467-018-3923-5. Epub 2018 Mar 15.
9
Podocytic Infolding Glomerulopathy in a Patient with Phospholipase A2 Receptor-Positive Membranous Nephropathy and Review of the Literature.足细胞内褶肾小球病合并磷脂酶 A2 受体阳性膜性肾病一例并文献复习
Nephron. 2021;145(5):496-502. doi: 10.1159/000515769. Epub 2021 May 7.
10
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.STARMEN 试验表明，在原发性膜性肾病中，与他克莫司和利妥昔单抗序贯治疗相比，皮质类固醇和环磷酰胺交替治疗更具优势。
Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7.

引用本文的文献

1
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.奥妥珠单抗和奥法木单抗在治疗伴有抗利妥昔单抗抗体的膜性肾病患者方面比利妥昔单抗更有效。
Kidney Int Rep. 2024 Dec 17;10(3):753-761. doi: 10.1016/j.ekir.2024.12.012. eCollection 2025 Mar.
2
Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial.基于人工智能的膜性肾病利妥昔单抗个体化治疗方案（iRITUX）：一项多中心随机对照试验方案
BMJ Open. 2025 Apr 2;15(4):e093920. doi: 10.1136/bmjopen-2024-093920.
3
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.
原发性膜性肾病中单克隆抗体治疗的应用进展。
Drugs. 2023 Apr;83(6):507-530. doi: 10.1007/s40265-023-01855-y. Epub 2023 Apr 5.
4
Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time.特发性膜性肾病患者白细胞介素-35 水平及其对缓解时间的预测价值。
Front Immunol. 2022 Aug 2;13:926368. doi: 10.3389/fimmu.2022.926368. eCollection 2022.
5
Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy.原发性膜性肾病及其对利妥昔单抗耐药的治疗进展。
Front Immunol. 2022 May 4;13:859419. doi: 10.3389/fimmu.2022.859419. eCollection 2022.